Nervgen Pharma (NGEN) Current Assets (2024 - 2026)

Nervgen Pharma (NGEN) posted quarterly Current Assets of $14.9 million for Q1 2026, down 9.15% quarter-over-quarter from $16.3 million in Q4 2025.

Nervgen Pharma (NGEN) Current Assets (2024 - 2026) Analysis & Trends

Nervgen Pharma (NGEN) has reported Current Assets for 3 consecutive years, with $14.9 million the latest figure, recorded in Q1 2026.

In Q1 2026, Current Assets changed N/A year-over-year to $14.9 million; the TTM figure through Mar 2026 stood at $14.9 million (changed N/A YoY), while the FY2025 annual figure was $16.3 million, up 20.13% from the prior year.
Current Assets retreated to $14.9 million in Q1 2026 per NGEN's latest filing, from $16.3 million in the prior quarter.
Across five years, Current Assets topped out at $16.3 million in Q4 2025 and bottomed at $13.6 million in Q4 2024.
Historically, Current Assets has averaged $14.9 million across 3 years, with a median of $14.9 million in 2026.
On a YoY basis, Current Assets climbed as much as 20.13% in 2025 and fell as far as 20.13% in 2025.
Nervgen Pharma's Current Assets stood at $13.6 million in 2024, then increased by 20.13% to $16.3 million in 2025, then dropped by 9.15% to $14.9 million in 2026.
Business Quant data shows NGEN's Current Assets at $14.9 million in Q1 2026, $16.3 million in Q4 2025, and $13.6 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Assets (Qtr)
1	Vertex Pharmaceuticals	139.90 Bn	132.05 Bn	2.84 Bn	12.54 Bn
2	Regeneron Pharmaceuticals	86.70 Bn	78.71 Bn	3.93 Bn	18.45 Bn
3	Argenx Se	65.73 Bn	60.55 Bn	1.37 Bn	8.07 Bn
4	Moderna	58.33 Bn	53.19 Bn	52.00 Mn	5.82 Bn
5	BeOne Medicines	42.16 Bn	37.07 Bn	1.53 Bn	7.22 Bn
6	Alnylam Pharmaceuticals	31.72 Bn	28.42 Bn	992.69 Mn	4.62 Bn
7	BioNTech SE	28.27 Bn	9.88 Bn	668.28 Mn	18.80 Bn
8	Insmed	27.61 Bn	26.45 Bn	358.27 Mn	1.63 Bn
9	Royalty Pharma	27.25 Bn	26.41 Bn	-	1.76 Bn
10	Nervgen Pharma	167.78 Mn	167.78 Mn	-	64.93 Mn

Download Data